Sample drugs. [Photo/businessdaily.co.ke]A UK based multinational drug making company, Clinigen has announced that it is seeking legal authority to set up shop in Kenya to sell its three cancer treating drugs.In a statement, the company said that it had granted Eisai Europe rights to seek permission from the Kenyan authorities to sell its three cancer drugs: Halaven, Fycompa and Lenyima.
Clinigen’s South Africa Managing Director Benjamin Miny in the statement said that they are seeking to meet the demand of cancer treatment by patients and their loved ones in the Sub Saharan Africa.
“We are able to leverage our extensive distribution network in the region and local expertise to enable access to this important medicines, helping to address the unmet medical needs of patients and their families across the Southern Africa,” Mr. Miny said.
The three drugs currently licensed in South Africa treat a variety of cancer ailments: Halaven is licensed to treat women with advanced metastatic breast cancer after they have undergone at least two chemotherapeutic regimens while Fycompa is used for stabilizing patients suffering from partial on set seizures and Lenyima is used for treating adult patients suffering various types of thyroid cancer.UK multinational seeks permit to sell new cancer drugs in Kenya.